Trial Profile

PRECIDENTD: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 23 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canagliflozin (Primary) ; Dulaglutide (Primary) ; Dapagliflozin; Empagliflozin; Glucagon-like peptide-1 receptor agonists; Liraglutide; Semaglutide; Sodium-glucose transporter 2 inhibitors
Indications Coronary artery disease; Heart failure; Myocardial infarction; Renal failure; Stroke; Type 2 diabetes mellitus
Focus Adverse reactions
Acronyms PRECIDENTD

Most Recent Events

20 May 2024 Planned number of patients changed from 9000 to 6000.
20 May 2024 Planned End Date changed from 30 Apr 2028 to 1 Mar 2029.
20 May 2024 Planned primary completion date changed from 30 Apr 2028 to 1 Mar 2029.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com